Review article · 2013 · Open access
Management of febrile neutropenia in the era of bacterial resistance
Therapeutic Advances in Infectious Disease, 1(1), 37–43 · Published 1 February 2013 · DOI 10.1177/2049936113475610
In brief
“Management of febrile neutropenia in the era of bacterial resistance” is a 2013 review article by Şehnaz Alp and Murat Akova, published in Therapeutic Advances in Infectious Disease. OpenAlex counts 49 citations as of 18 November 2026, which puts it in the top 9% of works published in 2013 by citations. It is open access: the full text is free to read at PubMed Central.
- Citations
- 49
- Most cited in
- 2021 (8)
- Field-weighted impact
- 0.28
- References
- 61
- Authors
- 2
Abstract
Managing cancer patients with fever and neutropenia must be considered as a medical emergency since any delay in initiating appropriate empirical antibacterial therapy may result in high rates of mortality and morbidity. Emerging antibacterial resistance in bacterial pathogens infecting febrile neutropenic patients complicates management, and choosing the type of empirical antimicrobial therapy has become a challenge. To further complicate the decision process, not all neutropenic patients are in same category of susceptibility to develop severe infection. While low-risk patients may be treated with oral antibiotics in the outpatient setting, high-risk patients usually need to be admitted to hospital and receive parenteral broad-spectrum antibiotics until the neutrophil levels recover. These strategies have recently been addressed in two international guidelines from the Infectious Diseases Society of America (IDSA) and the European Conference on Infections in Leukaemia (ECIL). This review gives a brief overview of current antimicrobial resistance problems and their effects in febrile neutropenic cancer patients by summarizing the suggestions from the IDSA and ECIL guidelines.
Cite this paper
Formatted from the catalogue record. Check names, capitals and page numbers against the paper before you submit.
APA 7
Alp, Ş., & Akova, M. (2013). Management of febrile neutropenia in the era of bacterial resistance. Therapeutic Advances in Infectious Disease, 1(1), 37–43. https://doi.org/10.1177/2049936113475610
MLA 9
Alp, Şehnaz, and Murat Akova. “Management of febrile neutropenia in the era of bacterial resistance.” Therapeutic Advances in Infectious Disease, vol. 1, no. 1, 2013, pp. 37–43. https://doi.org/10.1177/2049936113475610.
Chicago
Alp, Şehnaz and Murat Akova. 2013. “Management of febrile neutropenia in the era of bacterial resistance.” Therapeutic Advances in Infectious Disease 1 (1): 37–43. https://doi.org/10.1177/2049936113475610.
Harvard
Alp, Ş. and Akova, M. (2013) ‘Management of febrile neutropenia in the era of bacterial resistance’, Therapeutic Advances in Infectious Disease, 1(1), pp. 37–43. doi:10.1177/2049936113475610.
IEEE
Ş. Alp and M. Akova, “Management of febrile neutropenia in the era of bacterial resistance,” Therapeutic Advances in Infectious Disease, vol. 1, no. 1, pp. 37–43, 2013, doi: 10.1177/2049936113475610.
BibTeX
@article{alp2013management,
title = {{Management of febrile neutropenia in the era of bacterial resistance}},
author = {Alp, Şehnaz and Akova, Murat},
journal = {Therapeutic Advances in Infectious Disease},
year = {2013},
volume = {1},
number = {1},
pages = {37--43},
doi = {10.1177/2049936113475610},
url = {https://doi.org/10.1177/2049936113475610}
}
Download for a reference manager: BibTeX (.bib) · RIS for Zotero, Mendeley and EndNote (.ris)
Citations by year
| Year | Citations | Share of the best year |
|---|---|---|
| 2017 | 6 | |
| 2018 | 5 | |
| 2019 | 4 | |
| 2020 | 3 | |
| 2021 | 8 | |
| 2022 | 4 | |
| 2023 | 3 | |
| 2024 | 5 | |
| 2025 | 3 | |
| 2026 | 1 |
Its field-weighted citation impact is 0.28: it has been cited 0.28 times as often as the average work of the same field, type and year (1.00 is the world average).
Topic and keywords
Health Sciences › Medicine › Oncology › Neutropenia and Cancer Infections
- febrile neutropenia
- cancer patients
- antimicrobial resistance
- empirical antibiotic therapy
- broad-spectrum antibiotics
- oral antibiotics
- outpatient management
- hospitalization
Work with this paper
Most-cited papers in Medicine
- Yaşlı Kadınlarda Üreme SağlığıDemet Kokanalı, Yaprak Engin Üstün · Jinekoloji-Obstetrik ve Neonatoloji Tıp Dergisi · 2019 · 169,630 citations
- Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 CountriesHyuna Sung, Adalberto M. Filho, Mathieu Laversanne and 5 more · CA A Cancer Journal for Clinicians · 2021 · 119,885 citations
- “Mini-mental state”Marshal F. Folstein, Susan E. Folstein, Paul R. McHugh · Journal of Psychiatric Research · 1975 · 90,424 citations
- Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countriesFreddie Bray, Jacques Ferlay, Isabelle Soerjomataram and 3 more · CA A Cancer Journal for Clinicians · 2018 · 87,396 citations
- Hallmarks of Cancer: The Next GenerationDouglas Hanahan, Robert A. Weinberg · Cell · 2011 · 69,758 citations
Questions about this paper
How do I cite this paper in APA style?
Alp, Ş., & Akova, M. (2013). Management of febrile neutropenia in the era of bacterial resistance. Therapeutic Advances in Infectious Disease, 1(1), 37–43. https://doi.org/10.1177/2049936113475610
How many times has this paper been cited?
49 times, according to OpenAlex on 18 November 2026. Google Scholar and Scopus count different sets of sources, so their numbers differ.
Is this paper free to read?
Yes. It is open access at PubMed Central: sign in and open the full text from this page.
Who wrote this paper?
Şehnaz Alp, Murat Akova.
What is the DOI of this paper?
10.1177/2049936113475610, permanently at https://doi.org/10.1177/2049936113475610. Sign in and open it from this page.
Bibliographic data from OpenAlex (CC0), last checked 18 November 2026. ResearchGuru does not host this paper; once you are signed in, the links open it at the publisher or the repository that does.